Cyrla Zaltman

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

Bruce E. Sands, Peter M. Irving, Timothy Hoops et al. · The Lancet · 2022 · 277 citations

Immunology, Clinical Trials, Gastroenterology +7

Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial

Brian G. Feagan, Bruce E. Sands, William J. Sandborn et al. · ˜The œLancet. Gastroenterology & hepatology · 2023 · 208 citations

Systemic Treatment, Golimumab Monotherapy, Gastroenterology +4

Prevalence of periodontitis and DMFT index in patients with Crohn's disease and ulcerative colitis

Fernanda Brito, Fabiana Cervo de Barros, Cyrla Zaltman et al. · Journal Of Clinical Periodontology · 2008 · 158 citations

Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

Laurent Peyrin‐Biroulet, Ailsa Hart, Peter Bossuyt et al. · ˜The œLancet. Gastroenterology & hepatology · 2021 · 89 citations · Full text

Inflammation, Anti-inflammatory, Immunology +7

Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil

Rogério Serafim Parra, Júlio Maria Fonseca Chebli, Heda M B S Amarante et al. · World Journal of Gastroenterology · 2019 · 82 citations · Full text